Siegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.
KEY PRODUCTS
Reset all filters
01 1Siegfried AG
Reset all filters
01 1NALTREXONE
Reset all filters
01 1Switzerland
Reset all filters
01 1Active
Reset all filters
01 1Complete
Siegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.
GDUFA
DMF Review : Complete
Rev. Date : 2025-02-13
Pay. Date : 2024-11-15
DMF Number : 40414
Submission : 2024-12-20
Status : Active
Type : II
20
Siegfried Ag, based in Switzerland, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for Siegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.
One of their notable products is NALTREXONE, with a corresponding US DMF Number 40414.
Remarkably, this DMF maintains an Active status since its submission on December 20, 2024, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 13, 2025, and payment made on November 15, 2024, indicating their dedication to facilitating drug approvals, Categorized as Type II